Skip to main content

Provider Services

Our tests help to identify the genomic alterations driving a patient's cancer and match them with relevant targeted therapies, immunotherapies, and clinical trial options. We also provide decision support services, clinical trial matching, and technology solutions to help support all aspects of patient care.

Partnering with Providers

Foundation Medicine’s proven portfolio of tests and services offers the quality and commitment you need to help inform treatment strategies for all your advanced cancer patients. We work to bring the benefits of comprehensive genomic profiling into every practice. Discover in-depth genomic insights and a breadth of offerings to help predict patient benefit across multiple targeted therapies in multiple cancer indications.

Comprehensive Genomic Profiling Tests

Discover tissue AND blood-based FDA-approved comprehensive genomic profiling testing for all solid tumors with FoundationOne®CDx and FoundationOne®Liquid CDx. In addition, FoundationOne®Heme is a laboratory developed test for hematologic malignancies, sarcomas, or solid tumors where fusion detection is desired. 

Learn more about our tests

Comprehensive Services

We offer our customers comprehensive services that go beyond the test results such as with our Decision Support services. Medical Case Consulting is provided by a team of expert oncologists and pathologists to discuss patient results with you. Molecular Tumor Boards offer education at the practice level on the actionability of comprehensive genomic profiling for eligible institutions.

Learn more about Decision Support

Foundation Facts & Figures

Foundation Medicine has the most experience with comprehensive genomic profiling in the industry*. 

>400k

Patients Tested

>500

Peer-reviewed Publications

Latest Updates

Latest CDx Test

FoundationOne®Liquid CDx is the broadest FDA-approved blood-based comprehensive genomic profiling test, providing guideline-recommended genomic results from a simple blood draw.

Learn more about FoundationOne®Liquid CDx

Latest CDx Indication

Our FoundationOne®CDx tissue-based test now includes a pan-tumor companion diagnostic claim for a new indication of Keytruda® (pembrolizumab), for the identification of TMB-H patients (≥ 10 mutations/megabase) with unresectable or metastatic solid tumors.1

Learn more about our tests

References

* As defined by the number of cancer patients tested by Foundation Medicine in a clinical setting with comprehensive genomic profiling and the amount of evidence published by Foundation Medicine in a research setting about comprehensive genomic profiling 

1Unique patient profiles tested by Foundation Medicine and in Foundation Medicine database as of January 2020  

Important Safety Information

Select

FoundationOne CDx

FoundationOne®CDx is a qualitative next-generation sequencing based in vitro diagnostic test for advanced cancer patients with solid tumors and is for prescription use only. The test analyzes 324 genes as well as genomic signatures including microsatellite instability (MSI) and tumor mutational burden (TMB) and is a companion diagnostic to identify patients who may benefit from treatment with specific therapies in accordance with the approved therapeutic product labeling. Additional genomic findings may be reported and are not prescriptive or conclusive for labeled use of any specific therapeutic product. Use of the test does not guarantee a patient will be matched to a treatment. A negative result does not rule out the presence of an alteration. Some patients may require a biopsy. For the complete label, including companion diagnostic indications and important risk information, please visit www.F1CDxLabel.com. 

FoundationOne Liquid CDx

FoundationOne®Liquid CDx is for prescription use only and is a qualitative next-generation sequencing based in vitro diagnostic test for advanced cancer patients with solid tumors. The test analyzes 324 genes utilizing circulating cell-free DNA and is FDA-approved to report short variants in 311 genes and as a companion diagnostic to identify patients who may benefit from treatment with specific therapies (listed in Table 1 of the Intended Use) in accordance with the approved therapeutic product labeling. Additional genomic findings may be reported and are not prescriptive or conclusive for labeled use of any specific therapeutic product. Use of the test does not guarantee a patient will be matched to a treatment. A negative result does not rule out the presence of an alteration. Patients who are negative for companion diagnostic mutations should be reflexed to tumor tissue testing and mutation status confirmed using an FDA-approved tumor tissue test, if feasible. For the complete label, including companion diagnostic indications and complete risk information, please visit www.F1LCDxLabel.com.